Literature DB >> 22134702

Dose-dependent effects of thyroid hormone on post-ischemic cardiac performance: potential involvement of Akt and ERK signalings.

Iordanis Mourouzis1, Polixeni Mantzouratou, Georgios Galanopoulos, Erietta Kostakou, Nikolaos Roukounakis, Alexandros D Kokkinos, Dennis V Cokkinos, Constantinos Pantos.   

Abstract

The present study explored the effects of thyroid hormone (TH) treatment on post-ischemic cardiac function and potential implicated mechanisms. Acute myocardial infarction (AMI) was induced in mice by coronary artery ligation while sham-operated animals served as controls. This procedure resulted in a marked depression of cardiac function and significant reduction in TH levels in plasma. TH was given at a dose aiming to normalize T3 levels in plasma [AMI-TH (A)] and also at higher doses. The group of animals treated with the highest dose of TH, which displayed significantly increased mortality rate was included in the study [AMI-TH (B)]. In AMI-TH (A) mice, TH significantly improved left ventricular (LV) ejection fraction (EF%), [27.9% (1.4) in AMI versus 38.0 (3.1) in AMI-TH (A), P < 0.05], and favorably remodeled LV chamber while α-MHC was the dominant isoform expressed. In AMI-TH (B) mice, TH treatment resulted in increased mortality as compared to untreated mice (73% vs 47%, P < 0.05), while the favorable effect of TH was not evident in the survived animals. At the molecular level, TH, at the replacement dose, modestly increased p-Akt levels in the myocardium without any change in p-ERK levels. On the contrary, TH at the higher dose resulted in further increase in p-Akt along with an increase in p-ERK levels. In conclusion, TH appears to have a dose-dependent bimodal effect on post-ischemic cardiac performance and this effect may, at least in part, be mediated by a distinct pattern of activation of Akt and ERK signaling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22134702     DOI: 10.1007/s11010-011-1175-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  40 in total

1.  Thyroid hormone inhibits ERK phosphorylation in pressure overload-induced hypertrophied mouse hearts through a receptor-mediated mechanism.

Authors:  Jorge Suarez; Brian T Scott; Jorge A Suarez-Ramirez; Citlalic V Chavira; Wolfgang H Dillmann
Journal:  Am J Physiol Cell Physiol       Date:  2010-10-06       Impact factor: 4.249

Review 2.  Dangerous dogmas in medicine: the nonthyroidal illness syndrome.

Authors:  L J De Groot
Journal:  J Clin Endocrinol Metab       Date:  1999-01       Impact factor: 5.958

Review 3.  Acute myocardial infarction and thyroid function: new pathophysiological and therapeutic perspectives.

Authors:  Alessandro Pingitore; Yuefeng Chen; Anthony Martin Gerdes; Giorgio Iervasi
Journal:  Ann Med       Date:  2011-05-13       Impact factor: 4.709

4.  Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor alpha1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase.

Authors:  Koichiro Kinugawa; Mark Y Jeong; Michael R Bristow; Carlin S Long
Journal:  Mol Endocrinol       Date:  2005-04-14

5.  Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy.

Authors:  K Kinugawa; K Yonekura; R C Ribeiro; Y Eto; T Aoyagi; J D Baxter; S A Camacho; M R Bristow; C S Long; P C Simpson
Journal:  Circ Res       Date:  2001-09-28       Impact factor: 17.367

6.  Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats.

Authors:  Constantinos Pantos; Iordanis Mourouzis; Konstantinos Markakis; Nikolaos Tsagoulis; Matthew Panagiotou; Dennis V Cokkinos
Journal:  Basic Res Cardiol       Date:  2008-02-15       Impact factor: 17.165

7.  Thyroid hormone receptor alpha 1: a switch to cardiac cell "metamorphosis"?

Authors:  C Pantos; C Xinaris; I Mourouzis; P Perimenis; E Politi; D Spanou; D V Cokkinos
Journal:  J Physiol Pharmacol       Date:  2008-06       Impact factor: 3.011

8.  Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats.

Authors:  Constantinos Pantos; Iordanis Mourouzis; Konstantinos Markakis; Antonios Dimopoulos; Christodoulos Xinaris; Alexandros D Kokkinos; Matthew Panagiotou; Dennis V Cokkinos
Journal:  Eur J Cardiothorac Surg       Date:  2007-06-07       Impact factor: 4.191

9.  Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure.

Authors:  Kyle K Henderson; Sara Danzi; Jennifer T Paul; Greg Leya; Irwin Klein; Allen M Samarel
Journal:  Circ Heart Fail       Date:  2009-03-25       Impact factor: 8.790

10.  Early long-term L-T3 replacement rescues mitochondria and prevents ischemic cardiac remodelling in rats.

Authors:  Francesca Forini; Vincenzo Lionetti; Hossein Ardehali; Angela Pucci; Federica Cecchetti; Mohsen Ghanefar; Giuseppina Nicolini; Yoshihiko Ichikawa; Monica Nannipieri; Fabio A Recchia; Giorgio Iervasi
Journal:  J Cell Mol Med       Date:  2011-03       Impact factor: 5.310

View more
  22 in total

1.  M-protein is down-regulated in cardiac hypertrophy driven by thyroid hormone in rats.

Authors:  Andrei Rozanski; Ana Paula C Takano; Patricia N Kato; Antonio G Soares; Camilo Lellis-Santos; Juliane Cruz Campos; Julio Cesar Batista Ferreira; Maria Luiza M Barreto-Chaves; Anselmo S Moriscot
Journal:  Mol Endocrinol       Date:  2013-10-31

Review 2.  Translating thyroid hormone effects into clinical practice: the relevance of thyroid hormone receptor α1 in cardiac repair.

Authors:  Constantinos Pantos; Iordanis Mourouzis
Journal:  Heart Fail Rev       Date:  2015-05       Impact factor: 4.214

Review 3.  Thyroid hormone receptor α1 as a novel therapeutic target for tissue repair.

Authors:  Constantinos Pantos; Iordanis Mourouzis
Journal:  Ann Transl Med       Date:  2018-06

Review 4.  Thyroid hormones and cardiac remodeling.

Authors:  Dennis V Cokkinos; Stavros Chryssanthopoulos
Journal:  Heart Fail Rev       Date:  2016-07       Impact factor: 4.214

Review 5.  Cardioprotection and thyroid hormones.

Authors:  Alessandro Pingitore; Giuseppina Nicolini; Claudia Kusmic; Giorgio Iervasi; Paolo Grigolini; Francesca Forini
Journal:  Heart Fail Rev       Date:  2016-07       Impact factor: 4.214

6.  Gene polymorphisms and thyroid function in patients with heart failure.

Authors:  Ioannis Vasiliadis; Genovefa Kolovou; Vana Kolovou; Vasiliki Giannakopoulou; Maria Boutsikou; Niki Katsiki; Evaggelia Papadopoulou; Sophie Mavrogeni; Konstantina Sorontila; Costas Pantos; Dennis V Cokkinos
Journal:  Endocrine       Date:  2013-03-30       Impact factor: 3.633

7.  MuRF1 mono-ubiquitinates TRα to inhibit T3-induced cardiac hypertrophy in vivo.

Authors:  Kristine M Wadosky; Jessica M Berthiaume; Wei Tang; Makhosi Zungu; Michael A Portman; A Martin Gerdes; Monte S Willis
Journal:  J Mol Endocrinol       Date:  2016-02-09       Impact factor: 5.098

8.  Thyroid hormone signalling is altered in response to physical training in patients with end-stage heart failure and mechanical assist devices: potential physiological consequences?

Authors:  Stamatios Adamopoulos; Aggeliki Gouziouta; Polixeni Mantzouratou; Ioannis D Laoutaris; Athanasios Dritsas; Dennis V Cokkinos; Iordanis Mourouzis; Petros Sfyrakis; Giorgio Iervasi; Constantinos Pantos
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-07-02

9.  Inhibition of thyroid hormone receptor α1 impairs post-ischemic cardiac performance after myocardial infarction in mice.

Authors:  Iordanis Mourouzis; Erietta Kostakou; Georgios Galanopoulos; Polixeni Mantzouratou; Constantinos Pantos
Journal:  Mol Cell Biochem       Date:  2013-03-27       Impact factor: 3.396

10.  Cardioprotective effects of triiodothyronine supplementation against ischemia reperfusion injury by preserving calcium cycling proteins in isolated rat hearts.

Authors:  Lichao Fang; Zhiping Xu; Jian Lu; Lei Hong; Shigang Qiao; Lijun Liu; Jianzhong An
Journal:  Exp Ther Med       Date:  2019-10-21       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.